Table 1. Clinical characteristics of the study cohort.

N=1482		Advanced patients No.(%)	HLA-I LOH 676 (46%) No.(%)	HLA-I stable 806 (54%) No.(%)	P value	Significance
Median age (range)		58 (1-90)	59 (6-90)	57 (1-88)	0.011	*
Gender	Male	745	352	393	0.204	ns
	Female	737	324	413		
Median TMB (range)		7 (1-412)	7 (1-89)	6 (1-412)	< 0.0001	****
MSI	MSS	1097	546	551	<0.001	***
	MSI-H	37	8	29		
	MSI-U	348	122	226		-
Actionable mutations	TP53 mut	953	501 (74.1%)	452 (56.1%)	<0.001	***
	LRP1B mut	247	132 (19.5%)	115 (14.3%)	0.007	**
	EGFR mut	241	132 (19.5%)	109 (13.5%)	0.002	**
	KRAS mut	221	103 (15.2%)	118 (14.6%)	0.748	ns
	PIK3CA mut	215	91 (13.5%)	124 (15.4%)	0.295	ns
	APC mut	168	74 (10.9%)	94 (11.7%)	0.665	ns